Heartworm Disease in Dogs: Diagnostic Algorithm, Treatment Protocols, and Prevention Compliance

1. Introduction

Canine heartworm disease is caused by the filarial nematode Dirofilaria immitis, transmitted through the bite of infected mosquitoes of the genera Aedes, Culex, and Anopheles. The parasite migrates through the subcutaneous tissues, enters the venous circulation, and matures in the pulmonary arteries and right ventricle, leading to progressive vascular inflammation, pulmonary hypertension, and right‑sided congestive heart failure. Concurrent infections with other vector‑borne pathogens are common [3, 5], and subclinical infections contribute to a silent reservoir [5]. The geographic distribution of D. immitis continues to expand due to climate change and increased vector habitat [14], while the related species Dirofilaria repens also poses diagnostic and epidemiological challenges [8, 9]. A structured diagnostic algorithm, evidence‑based treatment protocols, and effective owner adherence to preventives are essential for disease control.

2. Diagnostic Algorithm

The American Heartworm Society (AHS) guidelines recommend a sequential testing approach combining antigen detection, microfilaria identification, and imaging. The algorithm is summarized in the decision tree below.

graph TD
    A[Canine patient with risk factors or clinical signs], > B{Antigen test (ELISA)}
    B, >|Positive| C[Confirm with microfilaria test]
    B, >|Negative| D{High suspicion?}
    D, >|Yes| E[Repeat antigen test after 3-4 weeks]
    D, >|No| F[Routine annual screening]
    C, > G{Microfilariae detected?}
    G, >|Yes| H[Quantify by modified Knott's test]
    G, >|No| I[Occult infection suspected]
    I, > J[Echocardiography / chest radiography]
    H, > K[Staging classification]
    J, > K
    K, > L[Class 1-4 based on clinical and imaging findings]
    L, > M[Initiate treatment protocol]

2.1 Antigen Testing

Commercial enzyme‑linked immunosorbent assays (ELISAs) detect circulating antigen of adult female D. immitis. The tests exhibit high sensitivity and specificity, although false negatives can occur early in infection (pre‑patent period of 5–7 months) or in male‑only infections. A positive result should be confirmed with a different test platform or a microfilaria detection method. The performance of point‑of‑care rapid tests has been compared with the modified Knott's test, showing variable agreement [6]; molecular tests (PCR) offer superior sensitivity for low‑level infections [10].

2.2 Microfilaria Detection

The modified Knott's test remains the reference standard for quantifying circulating microfilariae. One milliliter of EDTA‑anticoagulated blood is mixed with 10 ml of 2% formalin, centrifuged, and the sediment examined microscopically. Species differentiation (e.g., D. immitis vs. D. repens vs. Acanthocheilonema reconditum) is based on morphometric criteria. PCR‑based assays provide species‑specific confirmation and can detect subclinical infections [5, 10].

2.3 Imaging

Thoracic radiography reveals characteristic findings: enlargement of the main pulmonary artery segment, right ventricular hypertrophy, and peripheral pulmonary artery tortuosity and pruning. Echocardiography can directly visualize adult worms in the pulmonary arteries or right ventricle, particularly in heavy infections, and is essential for staging and prognostic assessment [12].

2.4 Staging Classification

Disease severity is classified into four stages based on clinical signs, radiography, and echocardiography (Table 1). A recent study correlated clinicopathologic variables with disease severity, noting that thrombocytopenia, eosinophilia, and elevated serum sialic acid concentrations are associated with more advanced stages [2, 4].

Table 1: Staging of Canine Heartworm Disease

3. Treatment Protocols

3.1 Adulticide Therapy

The only approved adulticide is melarsomine dihydrochloride, administered intramuscularly. The standard three‑injection protocol is as follows:

• Day 0: One injection (2.5 mg/kg)
• Day 30: One injection (2.5 mg/kg)
• Day 31: One injection (2.5 mg/kg)

This split‑dose regimen minimizes thromboembolic complications compared with the older two‑injection protocol. Strict exercise restriction is mandatory during the treatment period and for at least 6–8 weeks after the final injection to reduce the risk of pulmonary thromboembolism.

3.2 Adjunctive Therapy

Doxycycline is administered at 10 mg/kg orally twice daily for 30 days prior to adulticide therapy. Doxycycline targets the obligate intracellular endosymbiont Wolbachia pipientis, which is essential for worm metabolism, embryogenesis, and larval development. Elimination of Wolbachia reduces the inflammatory response after worm death and suppresses microfilariae production.

3.3 Non‑Arsenical Adulticide Protocols

A systematic review and meta‑analysis evaluated non‑arsenical protocols using moxidectin combined with doxycycline [13]. Monthly topical or injectable moxidectin (2.5 mg/kg topical or 0.17 mg/kg subcutaneous) plus doxycycline for 30 days resulted in adult worm death over 9–12 months. The efficacy is lower than melarsomine, but these protocols are indicated for patients with contraindications to arsenicals (e.g., severe caval syndrome, advanced renal disease). The meta‑analysis reported a pooled efficacy of approximately 85% for the moxidectin‑doxycycline combination, with fewer adverse effects than melarsomine [13].

3.4 Prevention Protocols

Monthly macrocyclic lactone administration remains the cornerstone of prevention. Ivermectin (6 µg/kg), milbemycin oxime (0.5 mg/kg), moxidectin, and selamectin are effective when given year‑round in endemic areas. A sustained‑release ivermectin formulation (FILAPREV) demonstrated high efficacy in field trials in Italy, maintaining therapeutic concentrations for 6 months [7]. Novel combination chewable tablets containing lotilaner, moxidectin, praziquantel, and pyrantel have also shown excellent preventive efficacy [15]. These multi‑month options may improve compliance.

4. Prevention Compliance

Owner adherence to monthly preventive administration is notoriously poor, with studies reporting that fewer than 50% of dogs receive year‑round prophylaxis. Strategies to improve compliance include:

• Use of long‑acting injectable formulations (e.g., moxidectin injectable every 6 months)
• Sustained‑release oral products [7]
• Combination products that cover multiple parasites (fleas, ticks, intestinal helminths) to simplify the regimen [15]
• Electronic reminders (smartphone apps, autoshipping programs)
• Client education on the life cycle, transmission risks, and consequences of lapses

Telemedicine platforms and remote diagnostic triage (refer to Telemedicine and Remote Diagnostic Triage in Veterinary Practice) can facilitate follow‑up and remind owners of upcoming doses. Integration with Cloud‑Based Diagnostic Data Integration for Herd Health Management can track compliance at the population level.

A practical checklist for veterinary staff is provided in Table 2.

Table 2: Strategies to Enhance Heartworm Prevention Compliance

5. Emerging Diagnostics and Biomarkers

In addition to traditional antigen and microfilaria tests, novel point‑of‑care devices (e.g., the Pluslife Mini Dock) have been evaluated for simultaneous detection of D. immitis and D. repens [6]. Serum sialic acid has been proposed as a biomarker of inflammation and infection severity in heartworm‑positive dogs [4]. Molecular characterization of isolates and vectors is critical for tracking epidemiological shifts [10, 14]. For a more detailed discussion of ELISA methodology, refer to Enzyme‑Linked Immunosorbent Assay (ELISA) in Veterinary Medicine.

6. Differential Diagnoses and Co‑Infections

Heartworm disease must be differentiated from other causes of chronic cough and right‑sided heart failure, including disseminated angiostrongylosis (Angiostrongylus vasorum), which can present with central nervous system involvement and sudden death [1]. Gastric dilatation and volvulus has been reported concurrently with heartworm in a dog with situs inversus, a rare co‑occurrence [12]. Co‑infections with Babesia spp., Ehrlichia spp., and Anaplasma spp. are common in endemic regions and may alter clinicopathologic parameters [3, 5, 11]. Renal pathology associated with D. repens infection has been described, including membranous glomerulonephritis [9].

7. Conclusion

Canine heartworm disease remains a significant health threat with expanding geographic range. A rigorous diagnostic algorithm incorporating antigen testing, microfilaria detection, and imaging is essential for accurate staging and treatment planning. Melarsomine‑based adulticide therapy combined with doxycycline and strict exercise restriction is the standard of care, with non‑arsenical moxidectin‑doxycycline protocols as alternatives. Improving owner compliance through long‑acting formulations, combination products, and digital reminders is critical for population‑level control. Ongoing molecular surveillance and biomarker development will further refine diagnostic and therapeutic approaches.

References

1. Dembowski M, Pütsch K, Delling C et al. Disseminated angiostrongylosis with involvement of the central nervous system as a cause of sudden death in a dog in Germany. BMC Vet Res. URL: https://pubmed.ncbi.nlm.nih.gov/42174611/
2. Kim M, Seo M, Cho J et al. Clinicopathologic variables according to disease severity in dogs with heartworm disease. BMC Vet Res. URL: https://pubmed.ncbi.nlm.nih.gov/42152057/
3. Khalife S, El Safadi D. Canine vector‑borne diseases in Lebanon: Unveiling prevalence trends and risk factors for public health and disease control. Vet Parasitol Reg Stud Reports. URL: https://pubmed.ncbi.nlm.nih.gov/42150803/
4. Yaghoobpour T, Faraji M, Nazifi S. Serum Sialic Acid as a Biomarker of Inflammation and Infection: Insights From Veterinary Medicine. Vet Med Int. URL: https://pubmed.ncbi.nlm.nih.gov/42148179/
5. Ranahewa DK, Dangolla A, Rajakaruna RS et al. Subclinical Infections of Babesia and Dirofilaria in Dogs Presented to a Veterinary Teaching Hospital: Evidence for a Silent Reservoir of Infection in Sri Lanka. Acta Parasitol. URL: https://pubmed.ncbi.nlm.nih.gov/42113286/
6. Sanders TL, Starnes A, Kelly MA et al. Comparative performance of the novel, point‑of‑care Pluslife Mini Dock Dirofilaria immitis/Dirofilaria repens detection test with the modified Knott's test in dogs. Parasit Vectors. URL: https://pubmed.ncbi.nlm.nih.gov/42104384/
7. Genchi M, Venco L, Fozzer M et al. Efficacy and safety of a sustained‑release formulation of ivermectin (FILAPREV) in preventing heartworm infection (Dirofilaria immitis) in dogs in two endemic areas of Italy. Parasit Vectors. URL: https://pubmed.ncbi.nlm.nih.gov/42087229/
8. Aguilar‑Elena R, Rodríguez‑Escolar I, Collado‑Cuadrado M et al. Global Research Trends in Emerging Zoonosis Due to (the Filarial Nematode) Dirofilaria repens (1955‑2025): A Bibliometric Analysis of a Climate‑Driven Expansion. Pathogens. URL: https://pubmed.ncbi.nlm.nih.gov/42075713/
9. Szabó KÉ, Aresu L, Müller L et al. Clinico‑pathological and renal morphological findings in dogs naturally infected with Dirofilaria repens. BMC Vet Res. URL: https://pubmed.ncbi.nlm.nih.gov/42069630/
10. Amarasinghe S, Ranasinghe K, Rodrigo W et al. First molecular characterization of Dirofilaria vector species and the distribution of canine dirofilariasis in Gampaha district, Sri Lanka. Front Cell Infect Microbiol. URL: https://pubmed.ncbi.nlm.nih.gov/42064220/
11. Julca LA, Salas‑Fajardo MY, Guevara S et al. Seroprevalence of zoonotic vector‑borne pathogens in domestic dogs from rural areas in northern Peru. Top Companion Anim Med. URL: https://pubmed.ncbi.nlm.nih.gov/42035833/
12. Stokowski S, Steuri SK, Lux C et al. Gastric Dilatation and Volvulus and Heartworm Disease in a Dog With Situs Inversus. Vet Radiol Ultrasound. URL: https://pubmed.ncbi.nlm.nih.gov/42011803/
13. Santiwattanatarm T, Sakcamduang W, Kongkaew C et al. A systematic review and meta‑analysis of non‑arsenical adulticide protocols using moxidectin and doxycycline for the treatment of adult heartworm infection in dogs. Curr Res Parasitol Vector Borne Dis. URL: https://pubmed.ncbi.nlm.nih.gov/42007372/
14. Monteiro ACMP, Ribeiro CM, Fehlberg HF et al. Emergence of Dirofilaria immitis in humid coastal zones: Epidemiological predictors and molecular characterization. Vet J. URL: https://pubmed.ncbi.nlm.nih.gov/41990946/
15. Young L, Reinemeyer CR, Abdelmoneim M et al. Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. URL: https://pubmed.ncbi.nlm.nih.gov/41943128/